Funded by LifeArc and Muscular Dystrophy UK (MDUK), the LifeArc Centre for Rare Mitochondrial Diseases is the first national mitochondrial disease treatment platform, aiming to connect specialists, patients, scientists, knowledge and infrastructure. It is a collaboration between the University of Cambridge, University College London, Newcastle University, in full partnership with The Lily Foundation.
We will establish a national platform to translate novel treatment strategies and biomarkers into clinical trials. Our over-arching aim is to develop new treatments for rare mitochondrial diseases.
The centre will be delivered in partnership with the Lily Foundation, the LHON Society and Muscular Dystrophy UK (MD-UK) to ensure our research addresses the highest priorities of patients and families affected by mitochondrial diseases. The Lily Foundation will lead our patient and public involvement and engagement (PPIE) activity and be an equal member of the centre management group, demonstrating our commitment to PPIE.
